Oppenheimer & Co’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$67.9M Buy
73,784
+4,417
+6% +$4.48M 0.83% 15
2025
Q4
$74.5M Buy
69,367
+2,353
+4% +$2.25M 1.06% 10
2025
Q3
$51.1M Sell
67,014
-5,719
-8% -$4.26M 0.62% 23
2025
Q2
$56.7M Sell
72,733
-624
-0.9% -$485K 0.75% 17
2025
Q1
$60.6M Buy
73,357
+674
+0.9% +$561K 0.91% 14
2024
Q4
$56.1M Sell
72,683
-5,284
-7% -$4.38M 0.84% 16
2024
Q3
$69.1M Sell
77,967
-1,596
-2% -$1.43M 1.05% 11
2024
Q2
$72M Buy
79,563
+4,344
+6% +$3.47M 1.14% 11
2024
Q1
$58.5M Buy
75,219
+2,533
+3% +$1.8M 0.97% 12
2023
Q4
$42.4M Buy
72,686
+2,702
+4% +$1.58M 0.78% 15
2023
Q3
$37.6M Buy
69,984
+3,397
+5% +$1.75M 0.78% 15
2023
Q2
$31.2M Sell
66,587
-825
-1% -$346K 0.62% 16
2023
Q1
$23.2M Sell
67,412
-5,002
-7% -$1.69M 0.49% 31
2022
Q4
$26.5M Buy
72,414
+5,520
+8% +$1.96M 0.6% 21
2022
Q3
$21.6M Sell
66,894
-1,336
-2% -$423K 0.51% 25
2022
Q2
$22.1M Buy
68,230
+6,194
+10% +$1.86M 0.48% 35
2022
Q1
$17.8M Buy
62,036
+3,106
+5% +$799K 0.32% 62
2021
Q4
$16.3M Buy
58,930
+1,737
+3% +$440K 0.28% 70
2021
Q3
$13.2M Sell
57,193
-4,785
-8% -$1.18M 0.25% 85
2021
Q2
$14.2M Buy
61,978
+3,592
+6% +$722K 0.26% 83
2021
Q1
$10.9M Sell
58,386
-24,000
-29% -$4.69M 0.22% 100
2020
Q4
$13.9M Buy
82,386
+11,150
+16% +$1.66M 0.29% 74
2020
Q3
$10.5M Buy
71,236
+25,076
+54% +$3.88M 0.26% 76
2020
Q2
$7.58M Sell
46,160
-2,969
-6% -$456K 0.2% 104
2020
Q1
$6.82M Sell
49,129
-807
-2% -$111K 0.21% 102
2019
Q4
$6.56M Buy
49,936
+1,817
+4% +$211K 0.16% 138
2019
Q3
$5.38M Sell
48,119
-9
-0% -$1K 0.15% 157
2019
Q2
$5.33M Sell
48,128
-13,724
-22% -$1.62M 0.14% 160
2019
Q1
$8.03M Buy
61,852
+1,200
+2% +$146K 0.21% 99
2018
Q4
$7.02M Buy
60,652
+2,162
+4% +$242K 0.22% 99
2018
Q3
$6.28M Buy
58,490
+1,538
+3% +$154K 0.16% 141
2018
Q2
$4.86M Sell
56,952
-464
-0.8% -$38.1K 0.13% 174
2018
Q1
$4.44M Buy
57,416
+3,215
+6% +$259K 0.11% 194
2017
Q4
$4.58M Buy
54,201
+2,338
+5% +$199K 0.12% 205
2017
Q3
$4.44M Sell
51,863
-4,725
-8% -$388K 0.12% 201
2017
Q2
$4.66M Sell
56,588
-9,429
-14% -$769K 0.13% 190
2017
Q1
$5.55M Sell
66,017
-3,754
-5% -$301K 0.16% 151
2016
Q4
$5.13M Sell
69,771
-2,366
-3% -$176K 0.15% 160
2016
Q3
$5.79M Buy
72,137
+2,970
+4% +$238K 0.17% 139
2016
Q2
$5.45M Buy
69,167
+11,934
+21% +$898K 0.16% 136
2016
Q1
$4.12M Sell
57,233
-9,821
-15% -$743K 0.13% 186
2015
Q4
$5.65M Buy
67,054
+6,712
+11% +$557K 0.17% 139
2015
Q3
$5.05M Buy
60,342
+10,342
+21% +$873K 0.15% 158
2015
Q2
$4.17M Sell
50,000
-6,093
-11% -$464K 0.12% 210
2015
Q1
$4.08M Sell
56,093
-22,748
-29% -$1.62M 0.11% 216
2014
Q4
$5.44M Buy
78,841
+5,728
+8% +$387K 0.16% 159
2014
Q3
$4.74M Sell
73,113
-45,446
-38% -$2.88M 0.14% 172
2014
Q2
$7.37M Sell
118,559
-16,863
-12% -$1.01M 0.22% 111
2014
Q1
$7.97M Buy
135,422
+5,269
+4% +$294K 0.24% 97
2013
Q4
$6.64M Sell
130,153
-7,854
-6% -$393K 0.21% 122
2013
Q3
$6.95M Buy
138,007
+13,874
+11% +$726K 0.24% 99
2013
Q2
$6.1M Buy
+124,133
New +$6.75M 0.24% 111

Other funds holding LLY

Oppenheimer & Co's LLY Position: Q1 2026 in Review

Oppenheimer & Co increased its Eli Lilly (LLY) stake by 6.4% in Q1 2026, buying an estimated $4.48M and bringing the position to 73,784 shares worth $67.9M. The position accounts for 0.83% of the portfolio, ranked #15.

Oppenheimer & Co first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $74.5M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Oppenheimer & Co held 73,784 shares of Eli Lilly worth $67.9M as of Q1 2026.
  • Oppenheimer & Co bought 4,417 Eli Lilly shares in Q1 2026, an estimated $4.48M.
  • Eli Lilly made up 0.83% of Oppenheimer & Co's portfolio in Q1 2026, its #15 holding.
  • Oppenheimer & Co first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Oppenheimer & Co's Eli Lilly position peaked at $74.5M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.